Oncolytic herpes simplex virus type-1 mutants reduce tumors in mice
Author Information
Author(s): Israyelyan Anna, Chouljenko Vladimir N, Baghian Abolghasem, David Andrew T, Kearney Michael T, Kousoulas Konstantin G
Primary Institution: Louisiana State University
Hypothesis
Can the NV1020 oncolytic herpes simplex virus type-1 mutants effectively inhibit primary and metastatic tumors in mice?
Conclusion
The OncSyn and OncdSyn viruses can effectively reduce primary and metastatic breast tumors in immunocompetent mice.
Supporting Evidence
- Both OncSyn and OncdSyn virus injections resulted in significant reduction of tumor sizes compared to control tumors.
- Virus treated mice showed a marked reduction of metastatic foci in lungs and internal organs.
- Mouse weights were not significantly impacted by any treatment during the study.
Takeaway
Scientists created special viruses that can help fight cancer by shrinking tumors in mice. These viruses work by making cancer cells fuse together and die.
Methodology
Mice were injected with either OncSyn, OncdSyn viruses, or PBS, and tumor sizes were measured over time.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Female Balb/c mice were used in the study.
Statistical Information
P-Value
p = 0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website